Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02313545
Other study ID # IAV-MAE-101-IL
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received December 7, 2014
Last updated March 12, 2018
Start date December 2014
Est. completion date March 2017

Study information

Verified date March 2018
Source Izun Pharma Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this open label study, 50 eligible women will be assigned to receive the investigational product (IZN-6NVS) - 2.5 g of cream/day for 14 days, followed by 3 applications per week for the next 4 weeks. Clinical assessment of the severity of vaginitis will be performed at baseline and after 2 and 6 weeks of treatment.

The study will evaluate safety, tolerability and efficacy of IZN-6NVS vaginal cream, in the treatment of atrophic vaginitis (AV) and desquamative inflammatory vaginitis (DIV).


Description:

This will be a Phase IB study comprised of three study groups:

- Group 1: Women who are naturally or surgically menopausal and symptomatic for AV, but who decline treatment with topical or systemic estrogen.

- Group 2: Women rendered menopausal as a result of pharmacologic treatment (including, but not limited to, aromatase inhibitor treatment, selective estrogen receptor modifiers (SERMs), and GnRH analog treatment), who decline treatment with topical or systemic estrogen.

- Group 3: Pre-menopausal women diagnosed with DIV.

The study will evaluate safety, tolerability and efficacy of IZN-6NVS vaginal cream, in the treatment of atrophic vaginitis (AV) and desquamative inflammatory vaginitis (DIV).

20 eligible women of groups 1 and 2 and up to 10 eligible women of group 3 will be assigned to receive 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks. Clinical assessment of the severity of vaginitis will be performed at baseline and after 2 and 6 weeks of treatment, which will be the end of the study. Patient reported symptom severity will be assessed by questionnaire at baseline and after 2 and 6 weeks of treatment, and at follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Women over age 18

2. For groups 1 and 2:

I. Self-reported amenorrhea for at least 12 months or documentation of menopause based on serum E2 = 150 pg/ml.

II. Self-reporting of at least one moderate to severe symptom of vaginal atrophy on a 4-point scale (0=none; 1=mild; 2=moderate; 3=severe):

- Vaginal dryness

- Vaginal discomfort or irritation

- Vaginal itching

- Vaginal pain associated with sexual activity

- Vaginal discharge

- Vaginal Malodor III. Clinical impression of atrophy based on examination of vaginal cytological smear.

IV. Vaginal pH >4.5

V. Endometrial thickness =5 mm as determined by US, with no abnormalities noted.

3. For group 3 (DIV): Clinical diagnosis of DIV in pre-menopausal women without estrogen deficiency.

4. For all groups:

I. Willing to comply with use of an intravaginal cream containing S. nigra, C. asiatica, and E. purpurea extracts.

II. Normal PAP smear within the last 3 years. III. Able to provide informed consent. -

Exclusion Criteria:

1. Subjects recruited in group 1 should not be actively treated for breast, uterine or ovarian cancer within the past year.

2. Vaginal bleeding of unknown cause within 60 days of enrollment

3. Vaginal infection requiring treatment within 30 days of enrollment

4. Any known allergy to the plant extracts in the study cream

5. Any serious disease; concomitant steroid use or sex hormone treatment

6. Endometrial thickness > 5 mm measured by ultrasound for women enrolled with diagnosis of atrophic vaginitis

7. Use of any vaginal moisturizer (e.g. Replens, Gynomonal) within 30 days of enrollment.

8. In groups 1 and 2, Use of any oral, transdermal, vaginal, or systemic estrogen or estrogen/progestin product within 30 days of enrollment.

9. Current urinary tract infection (UTI) (clinical complaints of UTI or dipstick urinalysis positive for nitrates or blood)

10. History of venous thromboembolic disease.

11. Use of another investigational agent within 12 weeks of screening.

12. Any medical or psychiatric condition that, in the investigator's opinion, would preclude the subject from complying with the study protocol, including the completion of questionnaires.

13. Subjects with DIV who are pregnant or trying to become pregnant will not be included in the study. Similarly, if a subject with DIV becomes pregnant during the study, that patient will be removed from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IZN-6NVS Cream
IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra. Cream concentration: 5%

Locations

Country Name City State
Israel Shaare Zedek Medical Center Jerusalem
United States Eastchester Medical Associates Bronx New York
United States Seattle Women's Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Izun Pharma Ltd

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety basis of the following parameters: - General Toxicity: Vital signs (temperature, blood pressure, pulse rate, respiratory rate). - Adverse events and toxicity Safety and tolerability will be evaluated on the basis of the following parameters:
General Toxicity: Vital signs (temperature, blood pressure, pulse rate, respiratory rate).
Adverse events and toxicity
6 weeks
Primary Change in composite score of vaginal symptoms as assessed by subject questionnaire from baseline At each time pion mentioned above, subjects will complete a Vaginal Symptoms questionnaire, subject will complete the questionnaire on their own. Day 0, Day 14, Day 42, Day 84
Primary Change in VMI (Vaginal Maturation Index) At each time pion mentioned above, Cells will be collected to determine the vaginal maturation index. Day 0, Day 14, Day 42
Primary Change in vaginal pH At each time pion mentioned above, Vaginal pH will be determined Day 0, Day 14, Day 42
Primary Change in pro-inflammatory cytokine levels in vaginal secretions At each time pion mentioned above, vaginal secretions will be sampled by swab and samples will be frozen for determination of cytokine levels at a later time piont. Day 0, Day 14, Day 42
See also
  Status Clinical Trial Phase
Completed NCT00984399 - Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen N/A
Completed NCT04079218 - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Phase 4
Recruiting NCT05953090 - VALOR: Vaginal Atrophy & Long-term Observation of Recovery N/A
Terminated NCT00816556 - A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Phase 3
Completed NCT00167921 - Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis Phase 1
Completed NCT04327947 - Evaluation of Gynecological Acceptability of 3 Health Care Products N/A
Recruiting NCT05118685 - Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis Phase 1
Completed NCT03294538 - Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis Phase 3
Completed NCT05058313 - Evaluation of the Safety and Performance of the MILTA GYNECO Vaginal Probe in Postmenopausal Women With Vaginal Atrophy N/A
Completed NCT02995694 - A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis Phase 3
Completed NCT02691936 - Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy N/A
Recruiting NCT06305494 - Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors
Completed NCT02195986 - A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis Phase 3
Recruiting NCT03981458 - Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis N/A
Completed NCT05396261 - a Flexible Wound Dressing for the Management of Genital Skin Conditions N/A
Completed NCT02869165 - Vaginal and Urinary Microbiome Trial Phase 4
Completed NCT02029053 - Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness Phase 0
Not yet recruiting NCT06176820 - Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause Phase 2/Phase 3
Recruiting NCT02733731 - The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis Phase 1
Withdrawn NCT02460302 - Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy Phase 2